Although breast cancers are thought to be less immune-sensitive, clinical trials of chemotherapy combined with anti-programmed cell death 1 or anti-programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitors atezolizumab or pembrolizumab in triple-negative breast cancer (TNBC) have shown favorable efficacy, making these combinations the standard of care for TNBC [1, 2]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.